Introduction: This Phase 2 clinical trial assessed the efficacy and safety of the novel antioxidative, renewable compound SkQ1 for topical treatment of dry eye signs and symptoms.
INTRODUCTION
The prevalence of dry eye syndrome worldwide ranges from 5% to 34% of the population [15] , and in the US is estimated to affect over 4% of men and almost 8% of women 50 years of age or older [21, 22] . Dry eye syndrome, which increases with age, is a multifactorial disease of the tears and ocular surface; symptoms include discomfort, visual disturbance, and tear film instability, with the potential for exposure of and damage to the ocular surface [7] . Dry eye is accompanied by increased osmolarity of the tear film, which can lead to morphological changes in the cornea and conjunctiva. Dry eye also involves inflammation of the ocular surface, which can result in apoptotic cell death in the corneal epithelium [3, 37] . Current therapies for dry eye are only palliative, focusing on replacement of tears to reduce symptoms. Thus, there is a need for drugs that directly address the causes of dry eye.
Oxidative mechanisms are believed to play an important role in the pathogenesis of dry eye syndrome. SkQ1 is a novel small molecule developed to reduce oxidative stress in cell mitochondria, targeting and neutralizing mitochondrial reactive oxygen species (ROS).
Mitochondria are one of the main sources of molecular oxygen consumption in the body [12, 29] . Natural antioxidants are not capable of penetrating mitochondria and neutralizing the excessive amounts of free radicals generated by these organelles. After ROS-dependent oxidation in the mitochondria, SkQ1 is reduced by the respiratory chain, making it a renewable active compound [26] . The localization of SkQ1 in mitochondria and its ability to regenerate make it a potentially effective pharmacological agent for treating pathologies of the eye associated with oxidative stress and lipid and protein peroxidation in the inner membrane of the mitochondria, and for the prevention of the onset or progression of dry eye syndrome.
As a topical ophthalmic formulation for dry eye, SkQ1 has demonstrated statistically significant positive results in a Phase 2 clinical trial in the US for reduction of both signs and symptoms in subjects with mild to moderate dry eye syndrome, as discussed in this article.
This study confirmed the results of a prior SkQ1 clinical study conducted in Russia and Ukraine [5] . An ophthalmic formulation of SkQ1, Visomitin, was approved in Russia in December 2011 and has since been marketed there as a prescription product. Russian studies with SkQ1 have involved 633 subjects; the US Phase 2 study enrolled 91 subjects.
MATERIALS AND METHODS
The Phase 2 US study was a randomized, double-masked, placebo-controlled, singlecenter, 29-day clinical trial. The study evaluated the safety and efficacy of SkQ1 ophthalmic solution in the environment and during challenge in the Controlled Adverse Environment (CAE SM ) chamber (Ora, Inc., Andover, MA, USA). The CAE is a clinical model used in the investigation of therapeutic agents to exacerbate the signs and symptoms of dry eye in a controlled manner by regulating humidity, temperature, airflow, lighting, and visual tasking within the CAE chamber. The CAE allows for standardized measurements of dry eye signs and symptoms and reduces variability [18] . The study included several dry eye sign and symptom parameters, described below.
Study Population
The subject selection process ensured that no subjects with underlying factors that could affect the conduct of the study or compromise subject safety enrolled in the study. All 91 subjects enrolled had clinical signs of mild to moderate dry eye for at least 6 months prior to study entry. The mean age of subjects was 62 years [standard deviation (SD) 10 .68]; 24 subjects were men and 67 were women. Key inclusion criteria at Visits 1 and 2 included a corneal fluorescein staining score of C2 in at least one region pre-CAE, a total lissamine green conjunctival score of C2 pre-CAE, a Schirmer's test score of B10 and C1 mm, a score of C2 in at least one symptom pre-CAE, and a demonstrated response to the CAE, based on Ora Calibra TM scales (Ora, Inc., Andover, MA, USA) as discussed in this article.
All subjects had to have demonstrated a reproducible dry eye response to the CAE at Visits 1 and 2. Exclusion criteria included no recent history of ocular surgery/procedures, no clinically significant (CS) slit lamp findings, no ongoing ocular infection or inflammation, no Restasis Ò (Allergan, Inc., Irvine, CA, USA) use within 30 days of Visit 1 (Day -7), no punctal plug use that was not stable within 30 days of Visit 1, no contact lens use within 7 days of Visit 1, and no use of medications known to cause ocular drying within 30 days of Visit 1.
Study Design
All subjects who met the inclusion and exclusion criteria were randomized 1: The primary and secondary efficacy analyses were performed on the intent-to-treat (ITT) population, which included all randomized subjects. Sensitivity analysis was performed on the per-protocol population, which excluded subjects with significant protocol deviations or who did not complete the study. Safety assessments were performed on the safety population, which included all subjects who received treatment from whom at least one safety measurement was obtained following the first dose of study drug.
Study Procedures

Efficacy Measures
The procedures used to assess efficacy measures are described below.
Dry Eye Signs
Corneal Fluorescein Staining Fluorescein staining of the cornea, commonly used to assess ocular surface damage, was assessed by the investigator using a slit lamp 3-5 min after instillation of 5 lL of 2% preservative-free sodium fluorescein solution into the inferior conjunctival cul-de-sac of each eye. A Wratten TFBUT The TFBUT test was performed in accordance with standard procedures. For each eye, two measurements were taken and averaged unless the two measurements were [2 s apart and were each \10 s, in which case, a third measurement was taken and the two closest of the three were averaged and used for analysis. If the difference between the two sequential pairs was the same (e.g., 3, 6, 9 s), then the median of the three readings was used 
Unanesthetized Schirmer's Test A sterile
Schirmer's strip was placed in the lower temporal lid margin for 5 min, at which point the length of moistened strip was recorded as an indication of tear production. A normal Schirmer's test results in C15 mm wetting of the paper after 5 min; lower values indicate more severe lack of tear production (a sign of dry eye syndrome).
Conjunctival Redness Conjunctival redness
was assessed by the investigator using the 5-point (0-4) Ora Calibra Conjunctival Redness Scale (0 = none, and 4 = most severe).
Lid Margin Redness Lid margin redness was assessed by the investigator using the Ora Calibra 4-point (0-3) Lid Margin Redness Scale (0 = none, and 3 = most severe).
Dry Eye Symptoms
Ocular Discomfort Ocular discomfort scores were subjectively graded by the subjects according to the 5-point Ora Calibra Ocular Discomfort Scale (0-4, with 0 = no discomfort and 4 = constant discomfort) [23] . Each eye was rated separately. Subjects assessed ocular discomfort at time 0 and every 5 min thereafter during the 90-min CAE exposures.
Subjects also assessed ocular discomfort at Visits 1, 2, and 4, before and after the CAE exposure, and also at Visit 3 when no CAE exposure occurred.
Dry Eye Symptoms and Ocular
Discomfort Other dry eye symptoms as well as ocular discomfort were assessed for both eyes of each subject at all scheduled visits, pre-CAE and post-CAE at Visits 1, 2, and 4 and once at Visit 3 (Day 15) when no CAE was performed.
The symptoms assessed by subjects were: overall ocular discomfort, burning, dryness, grittiness, and stinging, according to the 6-point (0-5) Ora Calibra TM Ocular Discomfort and 4-Symptom Questionnaire, in which 0 = none and 5 = most.
Drop Comfort Drop comfort was assessed for each eye by the subject immediately following initial dosing with the study drug and at 1 and 2 min following dosing using the Ora Calibra Drop Comfort Scale, where 0 = very comfortable and 10 = very uncomfortable.
Subjects also assessed drop comfort at 3 min following initial dosing using the Ora Calibra 
Safety Measures
The procedures used to assess safety measures are described below.
AEs
All AEs regardless of relationship to the test article were monitored, reported, and recorded throughout the study. 
Visual Acuity
Compliance with Ethics Guidelines
The study was Institutional review board-approved (Alpha IRB) and registered (Clinicaltrials.gov identifier: NCT02121301).
All procedures followed were in accordance with the ethical standards of the responsible 
RESULTS
Of the 91 randomized subjects, 87 subjects completed the study, and four discontinued, one for a protocol deviation and 3 by subject choice.
Results for several efficacy measures in this Phase 2 study indicated that SkQ1 was efficacious in treating dry eye signs and symptoms, even though findings did not meet the primary efficacy endpoints for this study of statistically significant treatment differences between SkQ1 and placebo in mean score pre-CAE for corneal fluorescein staining in the inferior region at Visit 4 (Day 29), and in mean score for worst dry eye symptom over the 7 days preceding Visit 4.
For dry eye signs, statistically significant results demonstrating SkQ1 efficacy occurred for corneal fluorescein staining, lissamine green conjunctival staining, and lid margin redness. For dry eye symptoms, statistically significant results occurred that indicated less ocular discomfort, dryness, and grittiness for SkQ1-treated subjects compared to subjects treated with placebo. Additional dry eye sign measurements, although not statistically significant, also indicated superior SkQ1 efficacy compared to placebo, and included corneal fluorescein staining for all other corneal regions at some time points, lissamine green staining for the central and nasal conjunctival regions, and blink rate.
Regarding safety, both doses of SkQ1 were safe. No serious AEs occurred, rates of AEs were similar between the SkQ1 treatment groups and the placebo group, and no subjects discontinued the study because of AEs. No CS safety issues were identified. Subjects reported good comfort and tolerability with SkQ1.
Results for each of the efficacy and safety parameters are discussed below.
Corneal Fluorescein Staining
As shown in Table 1 
Lissamine Green Staining
Using the Ora Calibra scale, the 0.155 lg/mL SkQ1 concentration was statistically significantly more effective than placebo (p = 0.0458) in reducing lissamine green staining for the central region at Visit 4 mean change from pre-to post-CAE, with scores of -0.12 (SD 0.313) for the 0.155 SkQ1 group and 0.00 (SD 0.000) for the placebo group (lower scores reflect less dry eye). In addition, for other 
Lid Margin Redness
There were statistically significant improvements (decreases) in lid margin redness scores at several time points for both SkQ1 concentrations compared to placebo. This occurred for the 1.55 lg/mL SkQ1 concentration at Visit 4 for: post-CAE (p = 0.0039), post-CAE change from Visit 2 post-CAE baseline (p = 0.0098), and pre-to post-CAE (p = 0.0224). Statistically significant efficacy also occurred for the 0.155 lg/mL SkQ1 concentration compared to placebo at Visit 4 for pre-CAE (p = 0.0319), post-CAE (p = 0.0028), and post-CAE change from Visit 2 post-CAE baseline (p = 0.0451). At Visit 3, SkQ1 0.155 lg/mL showed greater efficacy in reducing lid margin redness compared to placebo, although the differences were not statistically significant. between the SkQ1 groups and the placebo group or showed significance for the placebo. Table 2 continued Staining was statistically significant (p = 0.0113) compared to placebo.
OPI
Dry Eye Symptoms
Using the Ora Calibra Drop Comfort Scale, no statistically significant treatment differences were found in comfort levels for either concentration of SkQ1 compared to placebo at any of the time points evaluated (Visit 2 and Visit 3). Subjects in all three treatment arms generally rated the drops as comfortable. Using the Ora Calibra Drop Comfort Questionnaire, the most commonly chosen adjectives for all three treatment groups were positive, and included cool, comfortable, soothing, and refreshing. In addition, using the OSDI, subject responses regarding poor vision indicated fewer dry eye symptoms with SkQ1 use compared to placebo (at Visit 4, and Visit 4 change from baseline).
Safety Results
AEs
Both doses of SkQ1 ophthalmic solution (1.55 and 0.155 lg/mL) were safe and well tolerated as administered (BID) in this study and compared to placebo. No CS safety issues were identified with the use of SkQ1 ophthalmic solution at either concentration. Rates of ocular and non-ocular AEs were similar between the SkQ1 treatment groups and the placebo group. No serious AEs (SAEs) occurred, and no subjects were discontinued due to AEs. A total of 18 treatment-emergent AEs (TEAEs) occurred in Fig. 3 Ocular discomfort scores for SkQ1compared to placebo. Lower ocular discomfort scores indicate less discomfort. Ocular discomfort in the ITT population at Visit 4 (Day 29) pre-to post-CAE SM (with Visit 2 baseline change from pre-to post-CAE subtracted) was statistically significantly reduced in the SkQ1 0.155 lg/mL treatment group compared to the placebo group. Ocular discomfort was also notably lower in the SkQ1 1.55 lg/mL treatment group compared to placebo. CAE controlled adverse environment, ITT intent-to-treat this study: 7 TEAEs in the SkQ1 1.55 lg/mL group, 6 TEAEs in the SkQ1 0.155 lg/mL group, and 5 TEAEs in the placebo group; only three of these TEAEs were suspected of being related to treatment (2 TEAEs in the placebo group, and one TEAE in the SkQ1 0.155 lg/mL group), as shown in Table 3 .
No effects on visual acuity, IOP, slit lamp biomicroscopy tests, or dilated fundoscopy were observed. Any abnormal findings were reported at baseline and all were considered not CS. Regarding visual acuity, there were no CS differences in the group mean visual acuity (logMAR) scores between either of the SkQ1 treatment groups and the placebo group at any study visit. In addition, there were no CS differences noted among the treatment groups in the proportions of subjects with normal, abnormal (NCS), and abnormal (CS) slit lamp findings; the same was true for dilated fundoscopy findings. For IOP, there were no CS differences in mean IOP values or change in IOP between either concentration of SkQ1 and placebo at the two time points measured (Visit 1 and Visit 4).
Both
concentrations of SkQ1 were demonstrated to be safe and well tolerated ophthalmic products for use in dry eye subjects.
DISCUSSION
Oxidative Stress
Oxidative stress is involved in a variety of diseases, including cancer, Alzheimer's disease, Parkinson's disease, and cardiovascular, lung, and skin diseases, as well as ocular conditions including macular degeneration, uveitis, cataracts, corneal and ocular surface inflammation, and dry eye [6, 33] . Oxidative stress occurs with excessive levels of ROS, a type of free radical produced as a byproduct of cellular mitochondrial respiration. At normal levels, ROS is important in cell signaling and homeostasis [6] . ROS, oxidative stress, and inflammation are important factors in dry eye disease, for which inflammation is considered the primary mechanism [31] . The relationship between oxidative stress and inflammation in dry eye disease continues to be explored. High levels of ROS and oxidative stress markers have been identified in the tear film and conjunctiva of Sjogren syndrome patients [32] , in superficial punctate keratopathy in corneal epithelia [17] , in the tear film of dry eye patients [1] , and in animal models of dry eye [6] . Suspected TEAE was suspected of being related to the treatment, not suspected TEAE was suspected of not being related to the treatment, TEAEs treatment-emergent adverse events
Wakamatsu et al. [33] discussed antioxidant enzyme activity in the eye, with the highest levels found in the retina, lower levels in the sclera and cornea, and tears containing little such enzymatic activity [4] . Thus, except for the retina, the eye contains few protections against free radicals/ROS. It has been suggested that lactoferrin [24] or selenium [8] [19] , and increase the resistance of the lens to UV-irradiation [30] .
Dry Eye Models
Animal and human models of dry eye can reflect the environmental conditions that contribute to oxidative stress and dry eye. A rat model of dry eye using low-humidity airflow suggested a strong relationship between oxidative stress and corneal surface disorder [17] . A mouse model reflecting age-related ocular changes in the retina indicated that oxidative stress may play a role in retinal degeneration, and that the superoxide dismutase (SOD) enzyme may protect retinal pigment epithelium from age-related degeneration [9] .
Using this same mouse model, another study found that SOD1 may also provide protection for the dry eye parameters of tear function, the ocular surface, and the lacrimal gland [34] .
SkQ1 or related molecules have been shown to be active in a variety of animal models of illness believed to involve free radical damage.
These include rat models of H 2 O 2 and ischemia-induced heart arrhythmia, heart infarction, kidney ischemia, and stroke, studied both ex vivo and in vivo [2] . In addition, SkQ1 has shown efficacy in a number of eye disease models. Ocular preclinical studies with SkQ1 have included dry eye models in mice, and uveitis and retinal degeneration models in rats [14, 20, 30] . In the Phase 2 US clinical trial, SkQ1 was investigated using the CAE model to reflect the oxidative stress conditions of dry eye. The post-CAE results of this study as reported here indicate that SkQ1 treatment prior to CAE exposure protects the ocular surface from oxidative stress and provides a novel approach to dry eye treatment.
Preclinical Studies with SkQ1
Preclinical studies have shown that SKQ1 effectively modulates mitochondria membrane electric potential, reduces cellular destruction and damage caused by excessive concentrations of ROS, and decreases ocular surface inflammation [25, 38] . Based on a full range of animal toxicology studies, no adverse effects on general behavior or the central nervous system were observed (in rats orally administered SkQ1 at 0, 5, 25, or 100 mg/kg), or for cardiovascular parameters, pulse pressure, electrocardiography, body temperature, or clinical condition (in Beagle dogs orally administered SkQ1 at 0.00, 7.75, 77.5, or 775 lg/kg) (unpublished reports).
A mouse model study showed the efficacy of SkQ1 for the reduction of corneal staining, as discussed in the ''Dose Selection'' section above.
Possible Study Limitations
Limitations of some of the available diagnostic tools (e.g., Schirmer's test, corneal fluorescein staining) may contribute to mixed underlying etiologies. Use of several dry eye tests compensates somewhat for these test limitations. In addition, seasonality may contribute to a reduction in the effects of dry eye treatments as the drier season progresses. In addition, environmental factors, such as subjects' increased use of computers or reading or exposure to pollutants or certain medications, may also decrease the effects of dry eye treatments. Using a dry eye model (e.g., CAE chamber) that regulates humidity, temperature, airflow, lighting, and visual tasking, as used in the US Phase 2 study, can help control and minimize these potential confounding factors.
Prior SkQ1 Clinical Studies
The Phase 2 US clinical trial followed two clinical studies conducted in Russia. The first Russian clinical trial of SkQ1 demonstrated efficacy in treating signs and symptoms of dry eye compared to an artificial tear treatment [36] , after which Visomitin SkQ1 ophthalmic solution was approved in Russia (December 2011) and has since been marketed there as a prescription product. The second Russian clinical study assessed the safety, tolerability, and efficacy of Visomitin compared with placebo (the same artificial tears formulation used in the initial Visomitin study) [5] . 
CONCLUSIONS
This Phase 2 clinical trial indicated that SkQ1 is efficacious for the treatment of dry eye signs and symptoms and supported prior study results. SkQ1 was safe for use in the study's dry eye subjects, who found SkQ1 to be well tolerated and comfortable. Future studies will be conducted to confirm the efficacy and safety of SkQ1 ophthalmic solution. 
